CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0100584: EndocarditisHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug3052 zinc Wiki 1.00
drug879 Exebacase Wiki 1.00
drug560 Chloroquine Wiki 0.35
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D016470 Bacteremia NIH 1.00
D004696 Endocarditis NIH 1.00

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis

The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S. aureus) bloodstream infections (BSI), including right-sided infective endocarditis (IE). Patients will be randomized to receive a single intravenous dose of exebacase or placebo. Patients will receive SoCA selected by the investigators based on the protocol. Exebacase, a direct lytic agent, is an entirely new treatment modality against S. aureus. Exebacase is a recombinantly-produced, purified cell wall hydrolase enzyme that results in rapid bacteriolysis, potent biofilm eradication, synergy with antibiotics, low propensity for resistance, and the potential to suppress antibiotic resistance when used together with antibiotics. Exebacase represents a first-in-field, first-in-class treatment with the potential to improve clinical outcome when used in addition to SoCA to treat S. aureus BSI including IE.

NCT04160468 Staphylococcus Aureus Bacteremia Staphylococcus Aureus Endocarditis Drug: Exebacase Drug: Placebo
MeSH:Bacteremia Endocarditis
HPO:Endocarditis

Primary Outcomes

Measure: Clinical responder rate at Day 14 in the methicillin-resistant Staphylococcus aureus (MRSA) population

Time: Day 14

Description: TEAEs will be summarized by treatment group.

Measure: Treatment-emergent adverse events (TEAEs) through Day 60

Time: Through Day 60

Secondary Outcomes

Measure: Clinical responder rate at Day 14 in all S. aureus patients

Time: Day 14

Measure: 30-day survival in the MRSA population

Time: Through Day 30

Measure: Clinical responder rate at Day 60 in the MRSA population

Time: Day 60

Measure: Clinical responder rate at Day 60 in all S. aureus patients

Time: Day 60

Measure: Clinical responder rate at Day 60 in right-sided IE patients (all S. aureus and MRSA populations)

Time: Day 60


HPO Nodes